A FIVE‐YEAR STUDY OF A NEW HYPOTENSIVE AGENT

Publisher Website
Google Scholar
Abstract
Debrisoquine is a potent hypotensive drug which acts by inhibiting the release of noradrenaline at the sympathetic neuroeffector junctions. It is essentially an orthostatic hypotensive agent, lowering blood pressure primarily while the patient is in the upright posture. It has proved effective for 80% of a group of severely hypertensive patients treated for up to five years. Side effects, apart from postural hypotension, were few; no toxic complications were observed. Tolerance was not a problem, possibly because of the associated use of diuretics. Debrisoquine represents a marginal advance in hypotensive drug therapy over most previously available agents. It is especially recommended for the control of the severe forms of hypertension, including the malignant phase.